Pharmaceuticals

Global Nephrology Drugs Market Set for Strong Expansion, Reaching $24.32 Billion With 6.7% CAGR by 2030

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nephrology drugs market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Nephrology Drugs Market in 2030?

The nephrology drugs market has experienced robust expansion in recent years. It is anticipated to increase from $17.69 billion in 2025 to $18.74 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. The historic period’s growth can be attributed to the early uptake of antihypertensive agents, a rise in chronic kidney disease instances, the development of hospital infrastructure for renal care, innovations in dialysis and parenteral treatments, and enhanced awareness regarding kidney-related ailments.

The nephrology drugs market is projected to experience robust expansion over the coming years, reaching $24.32 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%.

This anticipated growth during the projection period stems from factors such as the creation of precision medicine specific to nephrology, the incorporation of AI into renal drug development, the broadening availability of homecare treatment options, increased capital allocation in biotechnology for kidney-related therapies, and the implementation of digital health monitoring systems for individuals with kidney conditions.

Key trends expected during the forecast timeframe encompass tailored kidney care approaches, the increasing occurrence of kidney disorders linked to hypertension, innovations in formulations for renal drugs, heightened understanding of chronic kidney disease management, and a greater uptake of renal treatments administered at home.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

What Drivers Are Influencing Production Trends In The Nephrology Drugs Market?

The increasing occurrence of chronic kidney disease (CKD) is anticipated to fuel the expansion of the nephrology drugs market. CKD involves impaired kidneys that struggle to filter blood effectively due to damage that typically progresses slowly over an extended period, leading to a buildup of waste in the body. Nephrology drugs are principally employed to manage CKD by improving kidney function and decelerating disease progression, thereby minimizing further bodily harm, which collectively propels the nephrology drug market. A notable example is data from June 2023, reported by Oxford Academic, an academic research platform of the UK-based Oxford University Press, indicating that the prevalence of CKD in the UK is forecast to increase by 4% from 8.27 million to 8.61 million individuals between 2022 and 2032. The expected stage distribution for 2032 is 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Consequently, the growing prevalence of chronic kidney disease is a key factor driving the growth of the nephrology drug market.

Which Segment Groups Are Influencing The Nephrology Drugs Market?

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

Which Trends Are Influencing The Development Of The Nephrology Drugs Market?

Leading companies in the nephrology drugs market are prioritizing approvals for innovative offerings, such as the U.S. Food and Drug Administration’s endorsement of Jardiance (empagliflozin), to better cater to the needs of their current consumers. Empagliflozin is a diabetic medication utilized for the management and treatment of type 2 diabetes mellitus. It belongs to the sodium-glucose co-transporter (SGLT-2) group of diabetic medicines. Empagliflozin lowers blood sugar levels by prompting the kidneys to release more glucose in the urine. For instance, in January 2023, Eli Lilly and Company, a US-based pharmaceutical firm, and Boehringer Ingelheim announced that the Food and Drug Administration approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which are being investigated as a potential therapy for lowering the risk of advancing kidney disease and cardiovascular death in adults with chronic kidney disease (CKD). Boehringer Ingelheim is a Germany-based pharmaceutical company.

Who Are The Core Companies Influencing Trends In The Nephrology Drugs Market?

Major companies operating in the nephrology drugs market are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Mylan N.V.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Which Regions Are Projected To Dominate The Nephrology Drugs Market In The Coming Years?

North America was the largest region in the nephrology drug market in 2025. Europe will be the second-largest growing region in the nephrology drug market in 2025. The regions covered in the nephrology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nephrology Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

Browse Through More Reports Similar to the Global Nephrology Drugs Market 2026, By The Business Research Company

Nephrology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Nephrologists Market Report 2020 2030 Covid 19 Implications And Growth 2026

https://www.thebusinessresearchcompany.com/report/nephrologists-market-global-report-2020-2030-covid-19-implications-and-growth

Nephrology And Urology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/nephrology-and-urology-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795